Summary
In a randomised, crossover trial the pharmacokinetics of furosemide (frusemide) were studied after single intravenous (30-minute infusion of 120mg) and oral (500mg) doses in 10 patients with chronic renal insufficiency (CLCR 16.7 ± 5.5 ml/min). Blood and urine samples were collected over 36 hours. Furosemide was analysed in serum and urine by a specific and sensitive HPLC method. After a lag time of 0.5 ± 0.5 hours (mean ± SD), peak plasma levels of 20.5 ± 12.0 mg/L were reached within 2.1 ± 0.7 hours. The mean plasma t½ of furosemide was 4.6 hours following intravenous administration and 11.8 hours after oral dosing (p = 0.0073). Within 24 hours, 14.9 ± 7.6% (IV) and 9.4 ± 5.5% (oral) of unchanged furosemide was excreted in the urine. The total body clearance was 46.3 ± 14.0 ml/min and the renal clearances amounted to 6.8 ± 3.9 (IV) and 5.5 ± 2.9 (oral) ml/min. The volume of distribution averaged 0.21 ± 0.07 L/kg. The absolute bioavailability of furosemide (67.9 ± 25.3%) was not affected by the chronic renal disease since it was comparable with data found in healthy subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreasen F, Hansen HE, Mikkelsen E. Pharmacokinetics of furosemide in anephric patients and in normal subjects. European Journal of Clinical Pharmacology 13: 41–48, 1978
Beermann B, Dalén E, Lindström B, Rosén A. On the fate of furosemide in man. European Journal of Clinical Pharmacology 9: 57–61, 1975
Beermann B, Midskov C. Reduced bioavailability and effect of furosemide given with food. European Journal of Clinical Pharmacology 29: 725–727, 1986
Branch RA, Roberts CJC, Homeida M, Levine D. Determinants of response to frusemide in normal subjects. British Journal of Clinical Pharmacology 4: 121–127, 1977
Brater DC, Seiwell R, Anderson S, Burdette A, Dehmer GJ, et al. Absorption and disposition of furosemide in congestive heart failure. Kidney International 22: 171–176, 1982
Burg MB. Tubular chloride transport and the mode of action of some diuretics. Kidney International 9: 189–197, 1976
Fine A, Kennedy AC, Tilstone WJ. Pharmacokinetics of frusemide in chronic renal failure. In Moorhead (Ed.) Dialysis, Transplantation, Nephrology. Proceedings of the Twelfth Congress of the European Dialysis and Transplant Association, Copenhagen, 1975. Vol. 12, pp. 338-343, Pitman Medical, Bath, 1976
Gladziwa U, Bares R, Klotz U, Dakshinamurty KV, Ittel TH, et al. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clinical Pharmacology and Therapeutics 50: 673–681, 1991
Grahnén A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. European Journal of Clinical Pharmacology 27: 595–602, 1984
Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. European Journal of Clinical Pharmacology 26: 197–207, 1984
Huang CM, Atkinson AJ, Levin M, Levin NW, Quintanilla A. Pharmacokinetics of furosemide in advanced renal failure. Clinical Pharmacology and Therapeutics 16: 659–666, 1974
Keller E, Hoppe-Seyler G, Schollmeyer P. Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clinical Pharmacology and Therapeutics 32: 442–449, 1982
Kelly MR, Cutler RE, Forrey AW, Kimpel BM. Pharmacokinetics of orally administered furosemide. Clinical Pharmacology and Therapeutics 15: 178–186, 1974
Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. Journal of Pharmacokinetics and Biopharmaceutics 11: 623–640, 1983
Lesne M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittel-Forschung 38: 160–163, 1988
Mandal AK, Visweswaran RK, Kaldas NR. Treatment considerations in acute renal failure. Drugs 44: 567–577, 1992
Odlind BG, Beermann B. Diuretic resistance: reduced bioavailability and effect of oral frusemide. British Medical Journal 280: 1577, 1980
Ponto LLB, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (part I). Clinical Pharmacokinetics 18: 381–408, 1990a
Ponto LLB, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (part II). Clinical Pharmacokinetics 18: 460–471, 1990b
Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, et al. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clinical Pharmacology and Therapeutics 24: 199–207, 1978
Rosenkranz B, Lehr KH, Mackert G, Seyberth HW. Metamizole-furosemide interaction study in healthy volunteers. European Journal of Clinical Pharmacology 42: 593–598, 1992
Smith DE, Gambertoglio JG, Vincenti F, Benet LZ. Furosemide kinetics and dynamics after kidney transplant. Clinical Pharmacology and Therapeutics 30: 105–113, 1981
Smith DE, Hyneck ML, Berardi RR, Port FK. Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients. Journal of Pharmaceutical Sciences 74: 603–607, 1985
Smith DE, Lin ET, Benet LZ. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metabolism and Disposition 8: 337–342, 1980
Tilstone WJ, Fine A. Furosemide kinetics in renal failure. Clinical Pharmacology and Therapeutics 23: 644–650, 1978
Waller ES, Hamilton SF, Massarella JW, Sharanevych MA, Smith RV, et al. Disposition and absolute bioavailability of furosemide in healthy males. Journal of Pharmaceutical Sciences 71: 1105–1108, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gladziwa, U., Böhm, R., Klotz, U. et al. Pharmacokinetics of Furosemide in Patients with Chronic Renal Failure. Drug Invest. 6, 137–143 (1993). https://doi.org/10.1007/BF03259733
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259733